Peptide education

Wolverine Blend

BPC-157 + TB-500 · BPC-157 + TB-500 Blend · bpc-157-tb-500-blend

Wolverine Blend is not a molecule; it is a marketing decision. The name covers BPC-157 plus TB-500 combination vials sold for injury recovery, usually 5 mg of each or 10 mg of each, and the branding does exactly what it is designed to do: make two uncertain peptides sound like one proven product. Neither component has controlled human outcome data, the fixed blend has never been studied in humans at all, and the TB-500 half may not even be the same substance from seller to seller. The closest human report anyone cites is a knee-pain chart review where a few patients got BPC-157 plus full-length thymosin beta-4, which is not this product.

Wolverine Blend packages two individually thin evidence stories into one vial that has never been studied as a product. The 10/10 and 5/5 vial sizes tell you what sellers package, not what works.

By the Peptides Media Editorial Team Editorial policy9 min read

Primary discussionRepair and recovery blend

Direct blend evidenceNo direct human trial

Common market routeUsually injection-centered

Main issueTB-500 identity and vial quality

Overview

Quick answer

Wolverine Blend is a marketed combination, not standalone BPC-157 and not standalone TB-500. BPC-157 has small and weak human evidence of its own, while TB-500 is usually treated by FDA as a thymosin beta-4 fragment. Human studies and registries for full-length thymosin beta-4 or ophthalmic timbetasin products do not automatically apply to gray-market TB-500 fragment vials or to a BPC-157 + TB-500 blend.

What is Wolverine Blend?

A market name for BPC-157 plus TB-500 combination products, sold through clinics, vendors, and gray-market channels for repair and recovery. It is not a standardized product: sellers vary by component amounts, and the name points to a concept, not an approved or tested medicine.

What do people use or discuss it for?

Tendon and ligament injuries, joint pain, muscle strains, wound healing, post-procedure recovery, and faster return to training, with some gut-complaint spillover from the BPC-157 side. Those are the goals buyers bring to it; none is a measured blend outcome.

What actual study and market details exist?

No controlled human study of the blend exists in the cited material. The concrete numbers are all component-level: oral BPC-157 phase 1 tablet schedules, a two-person BPC-157 IV pilot, intra-articular knee injections of about 4 mg BPC-157 with a few BPC plus thymosin beta-4 combination cases, and full-length thymosin beta-4 protocols for other routes entirely. Vendor vial sizes (5/5 mg, 10/10 mg) are packaging facts.

What should be separated?

Three things: what BPC-157 has shown (sparse early human data), what the TB-500 fragment has shown (identity plus rat and cell work, no human data), and what is actually inside a given seller's vial (unverified, with the TB-500 name drifting between fragment and full-length thymosin beta-4). Every confident recovery claim for the blend merges those into one answer, and that merge is the mistake.

Reported practice

Commonly reported protocol

Wolverine Blend community-reported use

Route

Subcutaneous injection

Typical amount

Blend vials are commonly sold as 5 mg BPC-157 plus 5 mg TB-500 or 10 mg plus 10 mg. Community use is usually described as amounts delivering roughly 250 to 500 mcg of each component per day.

Frequency

Once or twice daily in most descriptions

Duration

Most often 4 to 8 week runs

Community blend protocols. Community-reported patterns, not verified by controlled human trials and not a use recommendation. Full use-pattern detail

Evidence

Evidence snapshot

Best-supported statementMarketed for repair; no direct blend trial found

Vendor sources show that BPC-157 + TB-500 blends are marketed for repair and recovery, but the cited materials do not include a direct human clinical trial of the fixed blend.

Other PMID 34324435

BPC-157 componentSparse human evidence

BPC-157 has a registered oral phase 1 study, a two-person IV pilot, and a small retrospective knee-pain chart review. The review helps explain the blend's reputation, but it did not test a standardized BPC-157/TB-500 product or isolate either ingredient's effect.

NCT02637284 PMID 40131143 PMID 34324435 PMID 40789979

TB-500 componentFragment identity question

TB-500 is commonly tied to a thymosin beta-4 fragment, while many human thymosin sources involve full-length thymosin beta-4. Fragment, full-length peptide, and blend-vial evidence are separate.

FDA NCT00382174

Product qualityCOA language leaves injectable questions open

FDA materials warn that compounded or research-market peptide products raise identity, impurity, aggregation, sterility, and route-specific safety problems. A public vendor test may describe one sample, but the vial a buyer receives still needs its own identity, sterility, stability, and chain-of-custody support.

FDA Other

Claims

Common claims vs evidence

Claim	Human evidence	Mechanistic evidence	Anecdotal evidence	Verdict
The blend heals tendons, ligaments, muscle, or joints.	No direct human trial of the marketed blend is available. The closest blend-adjacent human report was a small retrospective knee-pain series in which a few patients received BPC-157 plus thymosin beta-4, not a standardized TB-500 fragment blend.	BPC-157 repair claims are usually linked to endothelial, fibroblast, nitric-oxide, and angiogenesis biology. TB-500 claims are usually linked to thymosin-related actin and cell-migration biology. BPC-157 and thymosin-related biology point toward repair pathways, but no controlled human study has measured healing with the commercial blend.	Clinic, vendor, forum, and gray-market discussion commonly uses repair, recovery, joint, tendon, and injury language. That discussion shows why people seek the blend, not that the blend caused recovery.	Too broad as a clinical claim. Wolverine Blend is a repair-themed market product built on indirect component evidence. PMID 34324435 PMID 40789979 PMID 38382158 Other
How much does BPC-157 evidence tell us about the blend?	BPC-157 has more human discussion than TB-500 fragment, but the available human evidence is still limited: one registered oral phase 1 study without posted outcome results here, a two-person IV pilot, and a small retrospective knee report.	BPC-157 preclinical work gives a repair rationale. It does not provide a finished blend dose, route, duration, or long-term safety profile.	Online users and clinics often treat BPC-157 as the local repair piece of the stack. That is a common interpretation, not a controlled comparison.	BPC-157 explains why the blend is discussed, but the commercial blend still needs direct human outcome data. NCT02637284 PMID 40131143 PMID 34324435
Can thymosin beta-4 evidence be applied to TB-500?	The human thymosin sources most often invoked around TB-500 are usually full-length thymosin beta-4 or ophthalmic product contexts. Those sources are not the same as injected TB-500 fragment inside a blend vial.	Thymosin beta-4 biology is tied to actin dynamics, migration, and wound repair. TB-500 fragment identity, exposure, and route still matter before transferring that biology to a human claim.	Vendor pages sometimes use TB-500, TB4, and thymosin beta-4 language in a way that makes the second ingredient hard to pin down.	Keep TB-500 fragment and full-length thymosin beta-4 separate. Blending the names together is one of the easiest ways to make the product sound more proven than it is. NCT00382174 NCT00832091 Other
The blend is safe if a vendor posts purity or a COA.	Vendor testing is not a human safety study, and FDA says compounded drugs are not FDA-approved or verified by FDA for safety, effectiveness, or quality before marketing.	Peptide products can fail through wrong identity, impurities, aggregation, degradation, sterility failures, endotoxin, wrong concentration, storage problems, or confusing labels. A blend doubles the active-ingredient identity question.	Public listings often pair "research use only" or "not for human consumption" language with repair, synergy, or recovery claims. That combination is a warning sign, not reassurance.	A COA can be one document to inspect, but the exact vial would still need lot-linked identity, per-component assay, sterility, endotoxin, stability, and chain-of-custody support. FDA Other
Wolverine Blend is a legal supplement or approved therapy.	No approved-drug or dietary-supplement status is available for the blend, and FDA compounding materials flag BPC-157 and TB-500-related substances for safety concerns.	Whether a peptide has a biological target does not settle legal status, product approval, or finished-product quality.	Research-use labeling and direct-to-consumer sales are common in the market. They keep the blend in research-use and gray-market territory, not approved-therapy territory.	Legal supplement or approved-therapy claims go beyond the current evidence. FDA

Bottom line

Main takeaway

If you just heard the name

Wolverine Blend is a BPC-157 plus TB-500 combo vial sold for injury recovery. Neither ingredient has controlled human outcome data, and the combination itself has never been studied.

If you are comparing repair peptides

Read the three files separately: BPC-157's sparse human data, the TB-500 fragment's identity-and-rodent file, and the full-length thymosin beta-4 record that keeps getting borrowed. The more a source blends them into one recovery promise, the less it is telling you.

What to check first

Look first for what does not exist: a direct blend trial, human exposure data for the TB-500 fragment, per-component assay and lot-level sterility documentation, and posted results for the registered BPC-157 oral study.

Identity

What it is

Wolverine Blend is the recovery market's most successful piece of branding: BPC-157 and TB-500 in one vial, named for a comic-book character famous for healing. It shows up on clinic menus, vendor listings, and protocol blogs as a fixed product, but there is no fixed product, only a format: typically 5/5 mg or 10/10 mg lyophilized vials with research-use disclaimers.

The BPC-157 half is a synthetic 15-amino-acid peptide with a large rodent repair literature and a human record consisting of an oral phase 1 registration without posted results, a two-person IV tolerability pilot, and an uncontrolled knee-pain chart review. The TB-500 half is usually a thymosin beta-4 fragment (Ac-LKKTETQ) whose direct evidence is an identity paper plus rat and cell wound-activity work, with FDA noting it has no human exposure data at all.

Stacking them is sold as synergy, but nothing in the cited material tests the combination in humans. What the blend actually does is additive uncertainty: two unproven components, one doubled identity question, and a label whose TB-500 half may be a fragment, full-length thymosin beta-4, or something the seller cannot document.

How people talk about it online

Online, Wolverine Blend is comeback-story fuel: nagging tendons, joint pain, strains, post-surgical recovery, getting back to training. Community protocols describe daily use delivering roughly 250 to 500 mcg of each component for 4 to 8 weeks, numbers borrowed from the separate BPC-157 and TB-500 conventions rather than from any blend study.

Vendor pages sell the vials with synergy language, third-party testing mentions, and research-use-only or not-for-human-consumption disclaimers in the same listing. That pairing, health claims next to a disclaimer saying the product is not for the use being implied, is itself the most honest information on the page.

Forum threads revolve around vial strength, reconstitution math, vendor trust, and perceived recovery, where outcomes are entangled with rest, rehab, time, and expectation. The discussions show real demand; they cannot show that the blend did anything.

Use context

Routes, doses, and cycle patterns

The sources here do not provide a controlled human regimen for the commercial BPC-157 + TB-500 blend. The concrete numbers come from component studies or vendor listings, so route, amount, and duration apply only to the specific item that reported them.

Human studies and product labels

Missing direct commercial blend regimen

Purpose: Blend-level repair, recovery, or safety
Context: No controlled human trial of the commercial blend in the cited sources
Route: No controlled human blend route found
Amount: No controlled human blend amount found
Frequency: No controlled human blend frequency found
Duration: No controlled human blend duration found

Vendor vial sizes are package facts. They help with product comparison, but they are not the same thing as a tested BPC-157 + TB-500 regimen.

Other PMID 34324435

BPC-157 oral phase 1 registration

Purpose: Early safety and pharmacokinetic development
Context: ClinicalTrials.gov record
Route: Oral tablets
Amount: Phase 1a used 1, 3, or 6 tablets with 1 mg per tablet; phase 1b used 3 tablets per dose
Frequency: Phase 1b listed every 8 hours
Duration: Phase 1b listed 2 weeks

This is BPC-157 development context. It did not test the blend for injuries or show that oral BPC-157 findings transfer to injectable blends.

NCT02637284

BPC-157 IV pilot

Purpose: Short-term tolerability finding
Context: Two-person human pilot
Route: Intravenous infusion
Amount: 10 mg in 250 cc saline on day 1; 20 mg in 250 cc saline on day 2
Frequency: Once daily for two study days
Duration: Two days

The pilot reported tolerability in two healthy adults, but it had no efficacy endpoint and did not test repeated blend use.

PMID 40131143

BPC-157 knee-pain chart review with BPC plus thymosin cases

Purpose: Knee-pain symptom reporting
Context: Retrospective clinic chart review
Route: Intra-articular injection
Amount: BPC-only cases often used 4 mg; combined cases included 2 mg BPC plus 3 mg thymosin beta-4, 3 mg plus 4.5 mg, and 4 mg plus 6 mg
Frequency: Single injection in the reported review
Duration: Follow-up varied in the chart review

This is the closest human blend-adjacent report, but it was retrospective, uncontrolled, subjective, and about a specific clinic mixture rather than a standardized TB-500 fragment blend.

PMID 34324435

Full-length thymosin beta-4 registry context

Purpose: Wound-related development context
Context: ClinicalTrials.gov registry for full-length thymosin beta-4
Route: Topical gel in venous-stasis-ulcer registry context
Amount: Summarized source does not provide a public amount
Frequency: Once daily in the registry context
Duration: Up to 84 days in the registry context

This helps show why thymosin biology is discussed in wound care, but it does not test TB-500 fragment or the blend.

NCT00832091

Real-world discussion

Community blend protocols

Purpose: Injury-recovery stacking discussion
Context: Vendor listings, clinics, and forums
Route: Subcutaneous injection
Amount: Blend vials are commonly sold as 5 mg BPC-157 plus 5 mg TB-500 or 10 mg plus 10 mg. Community use is usually described as amounts delivering roughly 250 to 500 mcg of each component per day.
Frequency: Once or twice daily in most descriptions
Duration: Most often 4 to 8 week runs

The blend combines the two most-discussed recovery compounds into one vial, which merges their separate uncertainties and adds blend-composition verification on top. Component protocols above are community conventions, not studied regimens. Shared here as context, not instruction.

What varies

Identity: check whether the claim means TB-500 fragment, full-length thymosin beta-4, or an unclear vendor label.
Route: oral BPC-157 registration, IV BPC-157 pilot data, intra-articular knee injections, topical thymosin beta-4 registries, and gray-market injectable vials are different situations.
Amount: component study numbers do not become a blend dose just because both names appear on one vial.
Frequency and duration: the clearest schedules here are study-specific component schedules, not Wolverine Blend instructions.
Quality: sterility, endotoxin, identity, per-component amount, degradation, storage, and COA chain of custody matter more for a blend than a headline purity percentage.

Human data

Human evidence

There is no human evidence for the blend as a blend; no controlled trial of the fixed combination exists in these sources. The component-level human data are thin on one side and absent on the other: BPC-157 has an oral phase 1 registration without posted results, a two-person IV pilot, and an uncontrolled knee chart review where a few patients also received full-length thymosin beta-4, while the TB-500 fragment has no human exposure data per FDA. Full-length thymosin beta-4 registries describe a different molecule and do not fill the gap. The blend's human case is, at best, a handful of uncontrolled combination knee injections that did not use a standardized TB-500 fragment product.

Evidence maturity

Evidence thins out step by step: preclinical component stories, sparse component human data, and no controlled trial of the blend as a product.

Component preclinical stories

BPC-157 repair models and thymosin-related actin and migration biology supply the repair-stack rationale.

Sparse component human data

BPC-157 has an oral phase 1 registry, a two-person IV pilot, and an uncontrolled knee chart review, while FDA found no human exposure data for TB-500 fragment.

Blend-level evidence

No controlled human trial of the fixed BPC-157 plus TB-500 blend exists; the closest report is a few uncontrolled BPC plus thymosin beta-4 knee cases.

Market reality

Gray-market 5/5 mg and 10/10 mg vials sell the stack with research-use disclaimers and unresolved TB-500 identity.

Study / evidence area	Population	Design	Product context	Main outcome	Limitations	Weight
Commercial BPC-157 + TB-500 blend Other	No direct human blend population found	Market blend with no controlled human blend trial found	Gray-market blend	A controlled human efficacy or safety trial was not found for the fixed commercial blend.	Vendor listings and clinic language show market use, not controlled human outcomes.	Weak
BPC-157 oral phase 1 record NCT02637284	Healthy volunteers in a registered early-phase study	ClinicalTrials.gov registration	BPC-157 component evidence	The registry describes oral tablet dose arms and a two-week repeated-dose phase, but the registry did not provide posted efficacy results.	Registration details are not clinical benefit or blend-dosing evidence.	Weak
BPC-157 IV pilot PMID 40131143	Two healthy adults	Two-person pilot study	BPC-157 component evidence	The pilot reported short-term tolerability after 10 mg IV on day 1 and 20 mg IV on day 2.	Very small, short, non-randomized, and not a blend efficacy study.	Very limited human
BPC-157 knee-pain chart review PMID 34324435	Sixteen knee-pain patients in a retrospective clinic series	Retrospective chart review	BPC-157 component and BPC plus thymosin beta-4 adjacent evidence	Most followed patients reported improvement; four patients received BPC plus thymosin beta-4 combinations.	No control group, no blinding, subjective outcomes, mixed knee problems, and not clearly a TB-500 fragment blend.	Weak uncontrolled human
TB-500 fragment identity and preclinical activity PMID 38382158	Identity literature, in vitro experiments, and rats	Analytical identity work plus preclinical screening	TB-500 component evidence	Sources support fragment identity and preclinical activity discussion, not human recovery efficacy.	Animal and in vitro findings are not human exposure, outcome, dosing, or blend safety.	Preclinical
Full-length thymosin beta-4 registry contexts NCT00382174 NCT00832091	Wound-related study populations depending on registry	ClinicalTrials.gov registry context	Adjacent full-length thymosin beta-4 evidence	Full-length thymosin beta-4 has human development contexts, including wound-related registries.	Registry presence and full-length thymosin beta-4 identity are not TB-500 fragment or Wolverine Blend.	Weak

Cautions

Safety and unknowns

Repeated blend exposure, injected gray-market use, and long-term safety need blend-specific human data. Component data cannot settle those questions by themselves.
TB-500 identity is a safety issue as well as an evidence issue. A source may mean a thymosin beta-4 fragment, full-length thymosin beta-4, or an unclear vendor label. Some public testing and regulatory materials describe mislabeled peptide products, impurity variation, and contamination concerns, so a label is only the start of the question.
Repair biology is not automatically benign. Angiogenesis, cell migration, inflammatory signaling, and tissue remodeling can matter in unwanted ways, especially when long-term human monitoring is absent.
BPC-157 and TB-500-related substances appear in FDA safety-risk and compounding discussions. That is a warning against assuming that research vials, compounded products, and studied materials are equivalent.

Product quality

A vial label is only a starting point

A BPC-157 + TB-500 blend has two active-ingredient identity questions, not one. The TB-500 component is especially vulnerable to naming drift.

Public vendor pages may show purity, COA, or third-party testing language while also using research-only disclaimers and repair claims.

Finished-product safety depends on sterility, endotoxin, concentration, degradation, storage, chain of custody, and per-component assay results.

Identity of both actives

BPC-157 and TB-500 both have to match the claimed material. Full-length thymosin beta-4 is not a silent substitute for TB-500.

Per-component amount

A total vial size does not verify how much of each peptide is present.

Sterility and endotoxin

Injection-centered products require contamination controls that a headline purity percentage does not cover.

Stability after reconstitution

Peptides can degrade or aggregate, and blend stability can differ from component stability.

COA chain of custody

A posted test is only as informative as the lot link, lab method, date, sample handling, and complete impurity profile behind it.

Mechanism

How it is proposed to work

The blend's appeal comes from combining two repair stories: BPC-157 is discussed around endothelial, fibroblast, gut, and soft-tissue repair signals, while TB-500 is discussed around thymosin-related actin movement, cell migration, angiogenesis, and wound biology.

BPC-157 mechanism papers and reviews often focus on nitric-oxide-linked effects, VEGF/VEGFR signaling, endothelial migration, fibroblast response, and tendon or gut models. These sources mostly explain plausibility.

TB-500 fragment discussion overlaps with thymosin beta-4 biology, but the fragment and full-length molecule are separate. Human thymosin beta-4 registries are not fragment outcome data.

The marketed "synergy" claim is still hypothetical. No human trial here tests whether BPC-157 and TB-500 work better together than either component alone.

The blend pairs two repair-associated peptides: BPC-157 (gut-derived, angiogenesis and NO-system themes) with TB-500 fragments (actin-dynamics lineage). There is no interaction research on the combination; the rationale is stacking two popular single-agent stories.

FAQ

Common questions

Is Wolverine Blend a studied BPC-157 plus TB-500 medicine?

No direct human clinical trial of the marketed fixed-dose blend is available. The evidence is mainly component evidence, adjacent thymosin beta-4 material, regulatory material, and market listings.

PMID 40789979 FDA

Does TB-500 evidence mean the same thing as thymosin beta-4 evidence?

No. TB-500 fragment and full-length thymosin beta-4 are separate unless a source actually studied the same material and route.

NCT00382174

Details

Technical details

Wolverine Blend technical details

Common name

Wolverine Blend / BPC-157 + TB-500 Blend

Product category

Gray-market peptide blend

Component 1

BPC-157, a synthetic 15-amino-acid peptide also associated with Bepecin and PL-14736 naming

Component 2

TB-500, commonly tied to thymosin beta-4 fragment Ac-LKKTETQ in identity literature

Related but different

Full-length thymosin beta-4 / timbetasin

Approval status

No approved therapeutic status found for the blend

Main grounded conclusion

Marketed for repair and recovery; no cited direct blend trial

Main reality check

Borrowing confidence from BPC-157, full-length thymosin beta-4, or vendor COA language

Practical takeaway

Market use depends on component evidence, label drift, identity, and product-quality limits.

Human PK data

None for the blend. Each component has its own (mostly unmeasured in humans) profile, and the combination has never been studied.

Sources

References

1.
FDA. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee 2026.
Accessed 2026-07-24.
FDA meeting page for the July 23-24, 2026 PCAC review of BPC-157, KPV, TB-500, MOTs-C, emideltide/DSIP, Semax, and Epitalon bulk substances, including the uses evaluated for each, briefing documents, and docket FDA-2025-N-6895.
2.
FDA. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks 2026.
Accessed 2026-06-08.
FDA summarizes potential significant safety risks and missing safety information for several nominated peptide bulk substances.
3.
FDA. Compounding and the FDA: Questions and Answers 2026.
Accessed 2026-06-08.
FDA explains that compounded drugs are not FDA-approved and that FDA does not verify their safety, effectiveness, or quality before marketing.
4.
PubMed. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing 2025.
PMID:40789979 Accessed 2026-06-08.
Narrative review that helps explain the recovery discussion but does not prove broad clinical recovery efficacy.
5.
ClinicalTrials.gov. ClinicalTrials.gov record NCT02637284 2015.
NCT02637284 Accessed 2026-06-08.
Trial record tracked for BPC-157 evidence mapping; no posted results were used for efficacy conclusions.
6.
PubMed. Focus on ulcerative colitis: stable gastric pentadecapeptide BPC 157 2012.
PMID:22300085 Accessed 2026-06-08.
Ulcerative-colitis review context; does not provide a practical regimen.
7.
PubMed. Simultaneous quantification of TB-500 and its metabolites in in-vitro experiments and rats by UHPLC-Q-Exactive orbitrap MS/MS and their screening by wound healing activities in-vitro 2024.
PMID:38382158 Accessed 2026-06-08.
In vitro and rat source; supports identity/activity mapping, not direct human exposure or efficacy.
8.
ClinicalTrials.gov. ClinicalTrials.gov record NCT00382174 2006.
NCT00382174 Accessed 2026-06-08.
Full-length thymosin beta-4 trial record; adjacent to TB-500 fragment discussion, not interchangeable evidence.
9.
ClinicalTrials.gov. ClinicalTrials.gov record NCT00832091 2009.
NCT00832091 Accessed 2026-06-09.
Full-length thymosin beta-4 phase 2 venous stasis ulcer registry record; no posted results were used for efficacy conclusions.
10.
PubMed. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study 2025.
PMID:40131143 Accessed 2026-06-15.
Two-person IV tolerability pilot; does not provide efficacy evidence or a usable regimen.
11.
PubMed. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain 2021.
PMID:34324435 Accessed 2026-06-15.
Small retrospective knee-pain chart review with BPC-157 and several BPC-157 plus thymosin beta-4 cases.
12.
Other. Public BPC-157 + TB-500 blend vendor page with TB-500/TB4 identity ambiguity 2026.
Accessed 2026-06-14.
Gray-market product source for COA limits and TB-500 versus thymosin beta-4 naming issues. No direct URL was present in the source packet.
13.
Other. Public BPC-157 + TB-500 blend vendor listing with repair and synergy framing 2026.
Accessed 2026-06-14.
Market-claim source for repair, recovery, and synergy language. No direct URL was present in the source packet.